2. UroToday Home
  3. Video Lectures

ASCO GU 2022

Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb
May 15, 2022
Details
Microbiome Research in Bladder Cancer - Laura Bukavina
May 15, 2022
Details
Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa
April 14, 2022
Details
Shared Decision-Making vs. Physician or Patient-Directed Decisions on Patient Quality of Life and Decision Satisfaction in Metastatic Prostate Cancer - Frank Schumacher
April 14, 2022
Details
The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran
April 14, 2022
Details
Results from the Phase 3 SPOTLIGHT Trial of 18F-rhPSMA-7.3 in Recurrent Prostate Cancer - David Schuster
April 14, 2022
Details
Sabizabulin in Phase 1b/2 Clinical Trials of Men With Metastatic Castration-Resistant Prostate Cancer Who Progressed on Androgen Receptor-Targeting Agents - Mark Markowski
April 14, 2022
Details
Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb
May 13, 2022
Details
Biological Pathways in Urothelial Carcinoma - Carissa Chu
April 12, 2022
Details
Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore
April 12, 2022
Details
Highlights of Urothelial and Prostate Cancer - 2022 GU ASCO Meeting - Scott Tagawa
April 12, 2022
Details
The Impact of Imaging and Therapeutics Advances in Nonmetastatic Castration-Resistant Prostate Cancer - David Penson
April 7, 2022
Details
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients with High-Grade Upper Tract Urothelial Carcinoma - Wesley Yip
April 7, 2022
Details
Practice Changing Publications in Urothelial Carcinoma - Deborah Kaye
April 3, 2022
Details
Risk Stratification for Localized Prostate Cancer - Matthew Cooperberg
March 29, 2022
Details
Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer - Brian Gonzalez
March 29, 2022
Details
Treatment Strategies in Advanced Urothelial Carcinoma - Stephen Boorjian
March 29, 2022
Details
A Real-World Study of PSA Response in Black and White Chemotherapy-Naive Prostate Cancer Patients Treated With Enzalutamide - Alicia Morgans
March 27, 2022
Details
Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore
March 27, 2022
Details
Significant Improvement With Continuous Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer – Axel Merseburger
March 25, 2022
Details
Real-World Treatment Trends in Metastatic Castration-Resistant Prostate Cancer - Pedro Barata
March 25, 2022
Details
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore
March 23, 2022
Details
Molecular Biomarkers in Upper-Tract Urothelial Carcinoma - Janet Kukreja
March 21, 2022
Details
The Future of Adjuvant and Neoadjuvant Therapy for Patients with Muscle-Invasive Bladder Cancer - Tracy Rose
March 21, 2022
Details
Penile Squamous Cell Carcinoma Somatic Alterations - W. Michael Korn
March 15, 2022
Details
ARASENS Trial Significantly Improves Overall Survival with Darolutamide in Combination with ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer - Matthew Smith
March 11, 2022
Details
TALAPRO-3 Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Neeraj Agarwal
March 11, 2022
Details
The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Rosenberg
March 11, 2022
Details
Treatment and Survival Differences in Patients With Urothelial Vs. Nonurothelial Bladder & Upper Tract Carcinomas - Jeanny Aragon-Ching
March 10, 2022
Details
The Next Wave of Novel Radiopharmaceuticals - Shahneen Sandhu
March 10, 2022
Details
Overall Survival With Stratification by Disease Volume and Metastatic Status – Analyses of the ARCHES Trial - Arun Azad
March 10, 2022
Details
Advanced Prostate Cancer Practice Informing Data Presented at ASCO GU 2022 - Oliver Sartor
March 10, 2022
Details
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng
March 10, 2022
Details
ARANOTE - Darolutamide in Addition to ADT Vs. ADT in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - Fred Saad
March 10, 2022
Details
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
March 4, 2022
Details
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
March 4, 2022
Details
AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt
March 4, 2022
Details
DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky
February 24, 2022
Details
Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski
February 24, 2022
Details
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
February 24, 2022
Details
Anticipated Data from Transformative Trials at ASCO GU 2022 - Oliver Sartor
January 6, 2022
Details
email news signup